Arrowsmith Genetics

Arrowsmith Genetics (AGx) is a preclinical stage, precision oncology company. AGx’s technology analyzes patient-specific tumour mutations, uses the results to identify new drug targets, and generates small-molecule therapy candidates for those targets. The company’s humanized yeast platform is fast, suitable for essential proteins, and finds binding sites that are unique to the targeted protein to minimize off-target effects.